Last A$0.11 AUD
Change Today 0.00 / 0.00%
Volume 40.5K
AVH On Other Exchanges
As of 8:01 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

avita medical ltd (AVH) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/7/14 - A$0.14
52 Week Low
12/4/13 - A$0.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AVITA MEDICAL LTD (AVH)

Related News

No related news articles were found.

avita medical ltd (AVH) Related Businessweek News

No Related Businessweek News Found

avita medical ltd (AVH) Details

Avita Medical Limited, a medical device company, develops and distributes regenerative medicine and respiratory products in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. The company develops and distributes tissue-engineered products for the treatment of wounds, scars, and other skin defects. Its lead product is ReCell, an autologous cell harvesting, processing, and delivery technology that enable collection of healthy skin cells for immediate treatment of existing scars created by burns, skin grafts, acne, acute wounds or surgery, and skin discolouration. The company also manufactures and sells a range of spacers, including Funhaler incentive asthma spacer for the paediatric market; and Breath-A-Tech spacer for the adolescent and adult markets. Avita Medical Limited is headquartered in Royston, the United Kingdom.

21 Employees
Last Reported Date: 09/30/13

avita medical ltd (AVH) Top Compensated Officers

Chief Financial Officer and Chief Operating O...
Total Annual Compensation: A$208.2K
Vice President of Research & Technology
Total Annual Compensation: A$198.7K
Company Secretary
Total Annual Compensation: A$36.0K
General Manager of EMEA
Total Annual Compensation: A$244.4K
General Manager of Asia Pacific
Total Annual Compensation: A$179.6K
Compensation as of Fiscal Year 2013.

avita medical ltd (AVH) Key Developments

Avita Medical Limited Presents More Positive ReCell Repigmentation Trial Results

Avita Medical Limited announced that new positive, statistically significant results have been obtained in a ReCell(R) Spray-on Skin(R) trial in patients suffering with depigmented skin lesions. Avita Medical's lead product, ReCell, a single-use autologous cell harvesting technology, has been used successfully in place of costly permanent laboratory facilities, which require special licensure, in the treatment of patients with vitiligo or piebaldism. ReCell technology works through the delivery of viable, pigment-producing cells harvested from a piece of the patient's own normally-pigmented skin and is administered by spraying the cells onto the affected area. The study involved 10 patients who participated in a randomised, within-subject controlled pilot trial facilitated by the Netherlands Institute for Pigment Disorders (Stichting Nederlands Instituut voor Pigmentstoornissen or SNIP).

Avita Medical Limited Replaces Ian Macpherson with Lou Panaccio as Chairman of Board, Effective from July 1, 2014

Avita Medical Limited announced that Mr. Lou Panaccio has been appointed to the role of Chairman of the Board, effective from 1 July 2014. Mr. Panaccio replaces Mr. Ian Macpherson who has served in the interim role since December 2013. Mr. Panaccio is currently a Non Executive Director of ASX50 company.

Avita Medical Limited's ReCell Spray-On Skin Demonstrates Superior Results Treating Hypopigmentation in Aesthetic Plastic Surgery Trial

Avita Medical Limited announced that its product, ReCell, has been proven in a clinical study in Germany to provide clinically superior results for the treatment of hypopigmented scars. The ongoing study by German-based Associate Professor Dr. Matthias Aust, found that areas treated with ReCell combined with a scar treatment technique called medical needling showed statistically significant repigmentation, while the areas treated with medical needling alone and not treated with ReCell, did not. In the study, each of the 18 participants had some hypopigmented scar area treated with needling, and other hypopigmented scar area treated with a combination of needling and ReCell. In the 12 months following the ReCell treatment, the participants were monitored using a medical device that detects levels of melanin in the skin. Medical needling, or percutaneous collagen induction, is a scar treatment approach that improves many properties of scar tissue, but often does not restore pigment, particularly for large scar areas. Dr. Aust hypothesized that adding ReCell to the scar treatment would result in greater repigmentation than can be achieved with the needling alone, and the results have shown that he was correct.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVH:AU A$0.11 AUD 0.00

AVH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVH.
View Industry Companies

Industry Analysis


Industry Average

Valuation AVH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.3x
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVITA MEDICAL LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at